Showing Clinical Research · 91–108 of 303
The comparative efficacy of rTMS and dTMS is a topic of debate among practitioners. Data from real-world clinical settings can be informative. Objective: To compare rTMS and dTMS devices for the treatment of MDD. Methods: This study included two groups of patients with MDD. Group 1 included 45 patients (30%…
Electroconvulsive Therapy (ECT) is believed to be an effective treatment for treatment resistant depression (TRD). However, ECT has been associated with major side-effects including cognitive sequel. Alternatively, deep Transcranial Magnetic Stimulation (dTMS) is another effective treatment for alleviating MDD symptoms. Reports comparing efficacy…
Currently, pharmacotherapy is the first-line treatment for Major Depressive Disorder (MDD). However, review of clinical studies has revealed that 2/3 of MDD patients do not respond sufficiently to pharmacotherapy alone. This in turn, has a considerable impact on MDD patients’ overall wellbeing and Quality of Life (QOL).…
A positive correlation between caffeine consumption and depression was recently reported. Biologically, caffeine inhibits adenosine A1 and A2A receptors. Researchers link A2A receptors with depression pathogenesis. They suggest a tight interaction between A2A receptors and Trk-B receptors which are upstream of Brain-Derived Neurotrophic…
The FDA cleared deep transcranial magnetic stimulation (Deep TMS) with the H7 coil for obsessive-compulsive disorder (OCD) treatment, following a double-blinded placebo-controlled multicenter trial. Two years later the FDA cleared TMS with the D-B80 coil on the basis of substantial equivalence. Objective:…
Despite the high lifetime prevalence and elevated disability rates, treatments for obsessive-compulsive disorder (OCD) have limited efficacy. Considering the abnormal connectivity in the cortical-striatal-thalamic-cortical loop circuits in OCD, several randomized controlled trials (RCTs) have addressed the efficacy of different non-invasive brain stimulation…
Current FDA-cleared TMS protocols for OCD include symptom provocation before stimulation, based on the idea that brain state may influence TMS effects. However, the size of any added clinical benefit from provocation had not been quantified across the literature. Objective: This systematic…
Deep Transcranial Magnetic Stimulation (dTMS) received FDA clearance in 2013 for the treatment of depression. As of yet, there are no post-marketing outcome data in “real world” practices. Objective: To examine a retrospective cohort of ten patients, ages 20-74, who received dTMS for treatment-resistant major depressive…
Obsessive-Compulsive Disorder (OCD) significantly impairs patients’ quality of life and frequently co-occurs with Major Depressive Disorder (MDD), complicating the interpretation of treatment outcomes. Transcranial Magnetic Stimulation (TMS) is FDA-approved for treatment-resistant OCD; however, there is limited naturalistic data on its effectiveness or predictors of…
The efficacy of deep TMS (dTMS) in depression has been shown in clinical trials. However, few dTMS studies have been conducted in naturalistic settings. Objective: To review response rates to dTMS treatment in a real-world clinical practice setting. Methods: This study includes eight patients, ages 25 to 57…
Deep TMS (dTMS) clinical trials using H-coil technology in Major depressive disorder (MDD) patients has shown significant outcomes following standardized treatment protocols. However, in naturalistic settings physicians adapt treatment protocols to individual clinical considerations achieving better outcomes. These varied therapeutic strategies may inform other physicians…
Deep transcranial magnetic stimulation (dTMS) is an emerging and promising treatment for major depression. In our study, we explored the effectiveness of a second antidepressant course of dTMS in major depression. Objective: To evaluate whether a second course of dTMS would be effective. Methods: Eight depressive patients who relapsed…
Modulating the function of the insular cortex could be a novel therapeutic strategy to treat addiction to a variety of drugs of abuse as this region has been implicated in mediating drug reward and addictive processes. The recent advent of the H-coil…
Repetitive transcranial magnetic stimulation (rTMS) has been recognized as a promising intervention for the treatment of post-stroke motor deficits. Objective: Here, we explore safety, feasibility, and potential effectiveness of high-frequency rTMS (HF-rTMS) delivered with the Hesed coil (H-coil) during active cycling on paretic lower extremity (LE)…
Deep transcranial magnetic stimulation (dTMS) is more beneficial in activating the leg muscle cortical representation. However, to date, no studies have evaluated the advantages of dTMS compared to repetitive transcranial magnetic stimulation (rTMS) in improving lower extremity motor function in subacute stroke patients. Objective:…
Clinical studies have shown the ability to treat neuropsychiatric disorders using H1 Coil Deep TMS. However, the electric field (E) distributions inside the brain induced by this coil when it is positioned on the scalp according to those clinical studies have not yet been estimated. Objective:…
Deep repetitive transcranial magnetic stimulation (DTMS), using the H7 coil, is an approved treatment for obsessive-compulsive disorder (OCD) by the United States Food and Drug Administration (US-FDA). The clinical efficacy and safety of accelerated regimens of DTMS have been previously studied extensively.…
Obsessive-compulsive disorder is one of the most common neuropsychiatric disorders with a higher lifetime prevalence than schizophrenia, often showing inadequate response to pharmacological and psychotherapeutic treatments. Objective: This study aimed to examine the efficacy of adjunctive deep transcranial magnetic stimulation (dTMS) in…
